Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Imara

Imara
2016 FOUNDED
IPO REG STATUS
1-10 EMPLOYEES
IPO LATEST DEAL TYPE (Announced)
$86.2M LATEST DEAL AMOUNT
9 INVESTORS
Description

Developer of novel therapeutics designed to treat patients with sickle cell disease and other hemoglobinopathies. The company's therapeutics reduces red blood cell sickling and blockage of blood vessels that are underlying causes of the pathology, enabling patients to get treatments for cell diseases.

Website
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 116 Huntington Avenue
  • 6th Floor
  • Boston, MA 02116
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Imara’s full profile, request a free trial.

Imara Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. IPO 14-Feb-2020 $86.2M 0000 Announced Clinical Trials - Phase 2
3. Early Stage VC (Series B) 18-Mar-2019 0000 0000 00000 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 14-Apr-2016 $31M $34M 0000 Completed Clinical Trials - Phase 1
1. Seed Round 26-Jan-2016 $3M $3M 00.00 Completed Clinical Trials - Phase 1
To view this company’s complete deal history including valuation and funding, request access »

Imara Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00 00 00 00 00.000
Seed 2,712,960 $0.001000 8% $1 $1 1x $1 2.73%
To view this company’s complete Cap Table, request access »

Imara Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immatics Venture Capital-Backed Tübingen, Germany 000 00000 00000000000 00000
00000 000000000000 Venture Capital-Backed Stockholm, Sweden 0 000.00 00000000000 000.00
000000000000000 Venture Capital-Backed Saint Louis, MO 0 00.000 000000000 00.000
00000 000000000000 Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
000000000 00000000 Venture Capital-Backed San Carlos, CA 000.00 0000000000 0 000.00
To view this company’s complete list of competitors, request access »

Imara Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Arix Bioscience Venture Capital Minority 000 0000 000000 0
OrbiMed PE/Buyout Minority 000 0000 000000 0
RA Capital Management Venture Capital Minority 000 0000 000000 0
Rock Springs Capital Hedge Fund Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Imara Executive Team (6)

Name Title Board
Seat
Contact
Info
Rahul Ballal Ph.D Chief Executive Officer & Board Member
Michael Gray Chief Financial Officer & Chief Operating Officer
Willem Scheele Chief Medical Officer
James McArthur Ph.D Co-Founder & Board Member

2 Former Executives

You’re viewing 4 of 6 executives. Get the full list »

Imara Board Members (15)

Name Representing Role Since Contact
Info
Barbara Dalton Ph.D Pfizer Ventures Board Member 000 0000
Carl Goldfischer MD Bay City Capital Board Member 000 0000
David Bonita MD OrbiMed Board Member 000 0000
David Mott New Enterprise Associates Chairman 000 0000
James McArthur Ph.D Self Co-Founder & Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 15 board members. Get the full list »